Skip to main content
Erschienen in: Supportive Care in Cancer 8/2018

10.03.2018 | Original Article

A brief psychoeducational intervention improves memory contentment in breast cancer survivors with cognitive concerns: results of a single-arm prospective study

verfasst von: Lori J. Bernstein, Graham A. McCreath, Joyce Nyhof-Young, Dilan Dissanayake, Jill B. Rich

Erschienen in: Supportive Care in Cancer | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

One in three breast cancer survivors experiences persistent cognitive changes that can negatively impact daily functioning and quality of life. In our cancer center, the largest tertiary cancer center in Canada, patients with self-reported cancer-related cognitive dysfunction (CRCD) are offered psychoeducation intended to reduce distress about CRCD symptoms and improve everyday cognitive performance, but evidence regarding this intervention’s impact is lacking. Here, we assess whether a 1-hour (h), individual psychoeducational intervention designed to promote self-management of CRCD symptoms can improve attitudes and coping with memory-related difficulties in women with breast cancer.

Methods

Breast cancer survivors with self-reported CRCD (N = 100) were assessed immediately before, immediately after, and 6 weeks following the intervention. Participants’ memory contentment, knowledge of CRCD, symptom distress, and self-efficacy to cope with symptoms were measured.

Results

Participants showed improvements in memory contentment immediately after the intervention (Cohen’s d effect size and 95% CI = 0.87 [0.58, 1.16]) and 6 weeks later (d = 0.77 [0.48, 1.05]). Significant improvements in secondary study outcomes, including knowledge of CRCD (d = 1.32 [1.01, 1.63]), symptom distress (d = − 0.82 [− 1.11, − 0.53]), and self-efficacy to cope with cognitive symptoms (d = 1.45 [1.14, 1.76]), were also observed.

Conclusions

A single, 1-hour psychoeducational intervention can achieve lasting and improved adjustment to memory symptoms in breast cancer survivors with self-reported CRCD. Further investigation using a randomized controlled study design is warranted. Comparisons with previously reported psychoeducational interventions for CRCD are made, and next steps for this research are discussed.
Literatur
12.
Zurück zum Zitat Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514. https://doi.org/10.1200/JCO.2016.68.5826 CrossRefPubMed Janelsins MC, Heckler CE, Peppone LJ, Kamen C, Mustian KM, Mohile SG, Magnuson A, Kleckner IR, Guido JJ, Young KL, Conlin AK, Weiselberg LR, Mitchell JW, Ambrosone CA, Ahles TA, Morrow GR (2017) Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 35(5):506–514. https://​doi.​org/​10.​1200/​JCO.​2016.​68.​5826 CrossRefPubMed
21.
Zurück zum Zitat Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancre V, Lange M, Castel H (2015) Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force Symposium and update since 2012. J Pain Symptom Manag 50(6):830–841. https://doi.org/10.1016/j.jpainsymman.2015.06.019 CrossRef Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancre V, Lange M, Castel H (2015) Impact of cancer and its treatments on cognitive function: advances in research from the Paris International Cognition and Cancer Task Force Symposium and update since 2012. J Pain Symptom Manag 50(6):830–841. https://​doi.​org/​10.​1016/​j.​jpainsymman.​2015.​06.​019 CrossRef
26.
Zurück zum Zitat Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, Garrett AM (2016) A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 122(11):1782–1791. https://doi.org/10.1002/cncr.29891 CrossRefPubMed Ferguson RJ, Sigmon ST, Pritchard AJ, LaBrie SL, Goetze RE, Fink CM, Garrett AM (2016) A randomized trial of videoconference-delivered cognitive behavioral therapy for survivors of breast cancer with self-reported cognitive dysfunction. Cancer 122(11):1782–1791. https://​doi.​org/​10.​1002/​cncr.​29891 CrossRefPubMed
29.
Zurück zum Zitat Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 24(11):1360–1367. https://doi.org/10.1002/pon.3769 CrossRefPubMed Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, Embree LM, Cernin PA, Leuchter AF, Ganz PA (2015) Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology 24(11):1360–1367. https://​doi.​org/​10.​1002/​pon.​3769 CrossRefPubMed
32.
Zurück zum Zitat Regan B, Wells Y, Farrow M, O'Halloran P, Workman B (2017) MAXCOG-maximizing cognition: a randomized controlled trial of the efficacy of goal-oriented cognitive rehabilitation for people with mild cognitive impairment and early Alzheimer disease. American J Geriatr Psychiatry 25(3):258–269. https://doi.org/10.1016/j.jagp.2016.11.008 CrossRef Regan B, Wells Y, Farrow M, O'Halloran P, Workman B (2017) MAXCOG-maximizing cognition: a randomized controlled trial of the efficacy of goal-oriented cognitive rehabilitation for people with mild cognitive impairment and early Alzheimer disease. American J Geriatr Psychiatry 25(3):258–269. https://​doi.​org/​10.​1016/​j.​jagp.​2016.​11.​008 CrossRef
34.
Zurück zum Zitat Lakens D (2013) Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol 4:863CrossRefPubMedPubMedCentral Lakens D (2013) Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol 4:863CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat R Core Team (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna R Core Team (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
41.
Zurück zum Zitat Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O’Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ (2018) Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 144(1):71–79. https://doi.org/10.1001/jamaoto.2017.2235 CrossRef Zer A, Pond GR, Razak ARA, Tirona K, Gan HK, Chen EX, O’Sullivan B, Waldron J, Goldstein DP, Weinreb I, Hope AJ, Kim JJ, Chan KKW, Chan AK, Siu LL, Bernstein LJ (2018) Association of neurocognitive deficits with radiotherapy or chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg 144(1):71–79. https://​doi.​org/​10.​1001/​jamaoto.​2017.​2235 CrossRef
Metadaten
Titel
A brief psychoeducational intervention improves memory contentment in breast cancer survivors with cognitive concerns: results of a single-arm prospective study
verfasst von
Lori J. Bernstein
Graham A. McCreath
Joyce Nyhof-Young
Dilan Dissanayake
Jill B. Rich
Publikationsdatum
10.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 8/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4135-z

Weitere Artikel der Ausgabe 8/2018

Supportive Care in Cancer 8/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.